|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effects of azidothymidine on protein kinase C activity and expression in erythroleukemic cell K562 and acute lymphoblastic leukemia cell HSB-2显示文摘Azidothymidine AZT 是当前为感染 HIV 的病人的治疗使用的 anti-retroviral 药之一。这药的几另外的效果在 vitro 被学习了,例如一些酶,房间增长的抑制,和 transferrin 受体表示的增加的改变。在这研究,我们调查了表情和 plasmatic 膜流动性分别地在二根癌症房间线,人的长期的 myeloid K562 和人的尖锐成淋巴细胞的 HSB-2 白血病房间由 AZT 导致了的蛋白质 kinase C PKC 活动, PKC 和 PKCII 的改变。结果证明在 HSB-2 房间的 PKC 活动和膜流动性在药孵化的 24 h 以后增加了。在 HSB-2 房间的 PKC 表示在 AZT 暴露的 48 h 以后减少了,当房间生长也减少了时。在 K562 细胞,当生长被禁止时,然而, PKC 和 PKCII 表情面对这药提高了。结果显示 AZT 在比禁止长期的 myeloid K562 房间的禁止尖锐成淋巴细胞的 HSB-2 白血病房间的生长是不太有效的。在 24 h 暴露以后,事实上, HSB-2 细胞生长减少了不到 K562 细胞生长。 | Veronica Carnicelli Anna Rita Lizzi Giancaterino Gualtieri Argante Bozzi Nicola Franceschini Antonio Di Giulio | 2015 | Acta Biochimica et Biophysica Sinica2015，47，4： | 1 |
| 2 | 免疫疗法联合立体定向放疗治疗非小细胞肺癌脑转移:一项AIRO多中心回顾性研究显示文摘背景与目的 通过意大利放射治疗和临床肿瘤学学会(Italian Association of Radiotherapy and Clinical Oncology, AIRO)的一项多中心回顾性研究,明确免疫疗法(immunotherapy, IT)和立体定向放疗(stereotactic radiotherapy,SRT)包括放射外科治疗(radiosurgery, RS)或大分割立体定向放疗(hypofractionated stereotactic radiotherapy, HFSRT)治疗非小细胞肺癌(non-small cell lung cancer, NSCLC)脑转移的疗效和毒性。方法 对来自19个意大利中心接受SRT+IT的NSCLC伴脑转移患者进行分析,并与单独接受SRT的对照组患者进行比较。结果 共纳入SRT+IT组100例和单独SRT组50例。接受SRT+IT的患者有更长的颅内局部无进展生存期(intracranial local progression-free survival, i LPFS)(经倾向性评分调整后,P=0.007)。在诊断为脑转移时接受IT合并有颅外进展的患者中(n=24),接受SRT后再进行IT与较好的总生存期(overall survival, OS)相关(P=0.037)。多因素分析显示组织学类型为非腺癌、卡氏体能状态(Karnofsky performance status,KPS)评分=70分以及接受HFSRT与显著减少的生存期相关(P值分别为0.019、0.017和0.007)。与SRT和IT治疗间隔>7天(n=10)相比,治疗间隔≤7天(n=90)与更长的OS相关(经倾向性评分调整后,P=0.008)。联合治疗耐受性良好。在放射性坏死方面,接受SRT+IT的患者与单独SRT的患者无显著差异。SRT和IT的治疗间隔对毒性发生率无影响。结论 SRT+IT是一种安全的联合治疗方法,与单独SRT相比,具有更长的i LPFS。 | Silvia SCOCCIANTI Emanuela OLMETTO Valentina PINZI Mattia Falchetto OSTI Rossella Di FRANCO Saverio CAINI Paola ANSELMO Paolo MATTEUCCI Davide FRANCESCHINI Cristina MANTOVANI Giancarlo BELTRAMO Francesco PASQUALETTI Alessio BRUNI Paolo TINI Emilia GIUDICE Patrizia CIAMMELLA Anna MERLOTTI Sara PEDRETTI Marianna TRIGNANI Marco KRENGLI NiccolòGIAJ-LEVRA Isacco DESIDERI Guido PECCHIOLI Paolo MUTO Ernesto MARANZANO Laura FARISELLI Pierina NAVARRIA Umberto RICARDI Vieri SCOTTI Lorenzo LIVI 王绿化(翻译/校对) | 2022 | 中国肺癌杂志2022，25，4： | 0 |
| 3 | Hepatitis C virus burden:Treating and educating people without prejudice显示文摘Hepatitis C virus(HCV)infection has a worldwide incidence of 1.1%.In Italy,60%of people who inject drugs(PWIDs)and are receiving assistance for substance use disorder are infected with HCV.However,this subset of patients has extremely limited access to care due to multiple factors,including alcohol abuse,psychological comorbidities,and homeless status.AIM To describe the impact of our HCV-dedicated service for substance use disorder(SSUD)service on PWIDs receiving anti-HCV therapy.METHODS A dedicated,multidisciplinary team was set up at the SSUD of Trento in October 2020 to provide antiviral treatment to HCV RiboNucleic Acid-positive patients with an active or previous history of substance abuse.The treatment was followed by a health education program.Patients were treated with Direct-Acting Antivirals(DAAs).Data were retrospectively analyzed to assess the efficacy of our dedicated program in terms of therapy completion,HCV eradication,and compliance(primary endpoint).The rate of HCV reinfection and DAA-related toxicity were also assessed(secondary endpoints).RESULTS A total of 40 patients were enrolled in the study:28(70.0%)were treated with Sofosbuvir/Velpatasvir,while 12(30.0%)received Glecaprevir/Pibrentasvir.At the time of inclusion in the study,36 patients were receiving opioid agonist maintenance therapy,whilst another 4 had just finished the treatment.37.5%had a history of alcoholism and 42.5%received concomitant psychiatric treatment.All 40 patients(100.0%)completed the therapy cycle and 92.5%of patients adhered to the program.All patients tested negative for viral load at the end of the treatment.There were no significant drug interactions with common psychiatric treatments and no side effects were observed.The sustained virological response was achieved in 92.5%of cases with good tolerability,although two patients discontinued treatment temporarily.After HCV eradication,one patient died from an overdose,another from complications of cirrhosis,and one reinfection occurred.CONCLUSION Very high adherence to therapy and good tolerability was observed in our series of HCV patients treated at the SSUD,regardless of the substance abuse condition.Further validation in a larger population is required. | Elettra Merola Elisa Menotti Giovanna Branz Andrea Michielan Sonia Seligmann Annora Ratti Flora Agugiaro Luisa Moser Giovanni Vettori Anna Franceschini William Mantovani Riccardo Pertile Giovanni de Pretis Cecilia Pravadelli | 2022 | World Journal of Hepatology2022，14，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员